1. ¹School of Health and Related Research, University of Sheffield, Sheffield, UK
2. ²Western General Hospital, Edinburgh, UK
3. ³Novartis Pharmaceuticals UK Ltd, Camberley, UK

Correspondence: Dr J Karnon, School of Health and Related Research, University of Sheffield, Regent Street, Sheffield S1 4DA, UK. E-mail: j.karnon@sheffield.ac.uk

Received 25 January 2007; Revised 21 June 2007; Accepted 21 June 2007; Published online 24 July 2007.

Abstract

Cost pressures and the need to demonstrate cost-effectiveness of new interventions require consideration of the costs of treating disease. This study presents analyses of resource use data covering 199 postmenopausal women who experienced a breast cancer recurrent event between 1991 and 2004 and were treated at the Western General Hospital, Edinburgh. Aggregate (5-year) treatment costs for alternative recurrent events were estimated, as well as the annual costs incurred by patients experiencing contralateral, locoregional, or distant recurrence, who remained alive without further recurrence for a year. The 95% confidence intervals for the 5-year costs of recurrence ranged from £10 000 to £37 000 for locoregional recurrence, and £14 500–£20 000 for distant recurrence. No evidence of significant variations in these costs across time periods between 1991 and 2004 was identified. Annual costs for patients remaining in the same health state showed high initial costs for contralateral and locoregional recurrence, with low costs in subsequent years, while costs associated with distant recurrence declined at a slower rate and plateaued at 4–5 years post-diagnosis. The cost estimates presented in this paper not only inform the magnitude of the resource consequences of breast cancer recurrences, but they are also better suited to informing cost-effectiveness analyses, which have a far greater role in allocating health-care resources.